ArticleACS omega2025
Spotlight on Endocannabinoids in Healthy Individuals Using Volumetric Absorptive Microsampling Combined with LC-MS/MS Analysis.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocannabinoids (eCBs) are crucial to regulating physiological function in the human body. This study investigates the applicability of volumetric absorptive microsampling (VAMS) for eCB analysis in blood samples. First, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to quantify a series of primary eCBs and eCB-like lipid mediators (i.e., AEA, OEA, SEA, PEA, LEA, 2-AG, and 2-OG). We then evaluated VAMS, considering several key parameters such as temperature, humidity, and hematocrit levels. This research systematically compared, for the first time, eCB levels in whole blood and plasma samples. We demonstrated an accuracy between 72.5% and 98.9%, with an interday and intraday precision below 8%, for all eCBs and eCB-like lipid mediators. The method exhibited minimal matrix effects, ranging from -15.0% to +9.0%. Most eCBs were stable under varying temperatures and storage conditions. However, drying time significantly affected the detected levels of 2-AG and 2-OG, suggesting that
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.